Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DK0B7G
|
|||
| Drug Name |
INZ-701
|
|||
| Drug Type |
Enzyme replacement
|
|||
| Indication | Hypophosphatemic rickets [ICD-11: 5C63.22] | Phase 1/2 | [1] | |
| Pseudoxanthoma elasticum [ICD-11: EC40] | Phase 1/2 | [2] | ||
| Company |
Inozyme Pharma Boston, MA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) | Target Info | Replacement | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04686175) A Phase 1/2, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 Followed by an Open-Label Long-Term Extension Period in Adults With ENPP1 Deficiency. U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT05030831) A Phase 1/2, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 Followed by an Open-Label Long-Term Extension Period in Adults With ABCC6 Deficiency Manifesting as Pseudoxanthoma Elasticum (PXE). U.S.National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of Inozyme pharma | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.